TNFSF10 and non-small cell lung carcinoma: Our data showed that, at the concentration of 60 ng/mL or lower, TRAIL showed no significant antitumor effect on A549 and H1299 cells, indicating that both NSCLC cell lines had low sensitivity or were resistant to TRAIL monotherapy (Fig. 1b,c).